Melane Sampson, Author at BioTuesdays

Developments

Immutep and Dr. Reddy’s Labs collaborate to commercialize oncology drug

Immutep (ASX: IMM; NASDAQ: IMMP) and Dr. Reddy’s Laboratories (BSE: 500124; NSE: DRREDDY; NYSE: RDY; NSEIFSC: DRREDDY) have announced that they have entered into a strategic collaboration and exclusive licensing...

December 8, 2025

Developments

Stanford’s Dr. Ghanouni receives Cum Laude award for RSNA presentation on CAPTAIN trial of TULSA v robotic radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the...

December 5, 2025

Developments

Ekso inks agreement to become exclusive U.S. distributor of MediTouch’s groundbreaking BalanceTutor rehab system

Ekso Bionics Holdings (NASDAQ: EKSO) has announced that it has entered into an agreement with Israel-based closely-held MediTouch (MediTouch) to become the exclusive authorized sales agent and distributor of MediTouch’s...

December 4, 2025

Developments

ADC announces updated data from trial of ZYNLONTA with glofitamab in r/r DLBCL

ADC Therapeutics (NYSE: ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in...

December 3, 2025

Developments

Black Diamond announces Phase 2 data for silevertinib in 1L NSCLC

Black Diamond Therapeutics (NASDAQ: BDTX) has announced topline data from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor...

December 3, 2025

Developments

Capricor reports positive topline results from Phase 3 study of Deramiocel in DMD

Capricor Therapeutics (NASDAQ: CAPR) has announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel for the treatment of Duchenne muscular dystrophy (DMD). HOPE-3 is a randomized...

December 3, 2025

Feature

Cardiol Therapeutics Advancing Life-Changing Therapies for Heart Disease, Showing Potential to Reverse Inflammation-Driven Structural Damage

Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is emerging as a leader in the development of anti-inflammatory and anti-fibrotic medicines designed to counteract the fundamental biological processes that drive...

December 2, 2025

Developments

Actinium reports ATNM-400 data showing potent efficacy in TNBC

Actinium Pharmaceuticals (NYSE American: ATNM) has announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) antibody radioconjugate, in hormone receptor positive (HR+), HER2 positive...

December 1, 2025

Executive Moves

Cadrenal appoints Dr. Lee Golden to BOD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the appointment of Lee Scott Golden, MD, to its board of directors (BOD) as an independent director, effective immediately. Dr. Golden currently serves as EVP and CMO...

December 1, 2025

Executive Moves

Dr. Mark Jaroszeski joins Aspire’s scientific team

Aspire Biopharma (NASDAQ: ASBP) has announced the addition of tenured professor, department of medical engineering, University of South Florida, Mark J. Jaroszeski, PhD, to its scientific team. Dr. Jaroszeski is a...

November 26, 2025

Author - Melane Sampson

Immutep and Dr. Reddy’s Labs collaborate to commercialize oncology drug

Stanford’s Dr. Ghanouni receives Cum Laude award for RSNA presentation on CAPTAIN trial of TULSA v robotic radical prostatectomy

Ekso inks agreement to become exclusive U.S. distributor of MediTouch’s groundbreaking BalanceTutor rehab system

ADC announces updated data from trial of ZYNLONTA with glofitamab in r/r DLBCL

Black Diamond announces Phase 2 data for silevertinib in 1L NSCLC

Capricor reports positive topline results from Phase 3 study of Deramiocel in DMD

Cardiol Therapeutics Advancing Life-Changing Therapies for Heart Disease, Showing Potential to Reverse Inflammation-Driven Structural Damage

Actinium reports ATNM-400 data showing potent efficacy in TNBC

Cadrenal appoints Dr. Lee Golden to BOD

Dr. Mark Jaroszeski joins Aspire’s scientific team

Subscribe